Mark Gustavson
Company: AstraZeneca
Job title: Senior Director & Global Head Computational Pathology Translational Science
Seminars:
Driving Computational Pathology in Oncology Drug Development 2:50 pm
• Computational Pathology provides greater analytical precision and potentially greater clinical accuracy – enabling identification of best patient populations for clinical response to oncology therapies • Quantitative Continuous Scoring (QCS) was developed to both quantify target expression in individual tumor's cells and to quantify spatial heterogeneity of expression • Discussing how to leverage Computational Pathology…Read more
day: Day One
H&E-Based Biomarker Profiling In Precision Medicine: Opportunities & Challenges 2:40 pm
Exploring opportunities, challenges and practical takeaways of H&E base biomarker Profiling across a variety of different applications (research, drug development, the clinic)Read more
day: Day Three Track A
Panel Discussion: AI and Digital Pathology – Enabling Next-Gen Treatments & Diagnostics 2:15 pm
What impact does artificial intelligence (AI) and digital pathology (DP) have on biomarker strategy and drug development? How novel treatment modalities are driving innovative assays and AI-powered scoring frameworks How AI-powered biomarkers can be deployed for trial enrollment and patient selectionRead more
day: Day Three Track A
TRACK A: Biomarker Discovery & Translational Development 10:15 am
day: Day Three Track A
Fireside Chat: Next Generation Digital Pathology Diagnostics… A Revolution in the Making 2:20 pm
• Evolution of quantitative IHC including QCS • Incorporating digital pathology including AI in the discovery phase • Navigating the DP landscape • Impact of digital pathology on patient careRead more
day: Day One